Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 27.
doi: 10.1111/apt.70348. Online ahead of print.

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Raffaella Viganò  1 , Alessandro Loglio  2 , Clara Dibenedetto  3 , Paola Carrai  4 , Silvia Martini  5 , Ilaria Lenci  6 , Bianca Magro  7 , Sara Conti  8 , Paolo Angelo Cortesi  8 , Chiara Mazzarelli  1 , Chiara Becchetti  1 , Giovanni Perricone  1 , Monica Cucco  1 , Marco Carbone  1 , Donatella Cocchis  9 , Elisa Farina  2 , Luisa Pasulo  2 , Mauro Viganò  2 , Michele Sagasta  3 , Elisabetta Degasperi  3 , Davide Ghinolfi  4 , Pietro Lampertico  3   10 , Stefano Fagiuoli  2   11 , Luca Saverio Belli  1 ; INSIGHT‐B study group
Affiliations

Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study

Raffaella Viganò et al. Aliment Pharmacol Ther. .

Abstract

Background & aims: Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside analogues (NAs) plus HBIG for long-term prophylaxis against hepatitis B virus (HBV) recurrence after liver transplant (LT). The aim of this study was to evaluate the safety of HBIG withdrawal in a cohort of LT recipients on long-term HBIG+NAs.

Methods: All patients under third-generation NAs + HBIG and who adhered to the INSIGHT-B protocol were followed up after HBIG withdrawal, in a multicentre, prospective, Italian cohort study, to evaluate the risk of HBV reactivation. The probability of HBsAg reappearance after HBIG withdrawal, stratified by presence of HCC at LT, was estimated through Kaplan-Meier curves and Log-rank tests.

Results: Between February 2021 and January 2024, 222 liver transplant (LT) recipients withdrew HBIG 11.6 (IQR 6.7-17.0) years after LT and were followed up for a median time of 24 months. After HBIG withdrawal, Hepatitis B surface antigen (HBsAg) reappearance was observed in 12 patients (5.4%) with a cumulative 1-, 2- and 3-year recurrence rate of 4.08%, 5.36% and 6.89% respectively. HBsAg serum levels remained very low over the entire period of observation (median 9 months, range 3-20), and in four cases fluctuated around the detectability threshold. In all cases, HBV-DNA persisted undetectable, liver function tests (LFTs) remained within the normal range, and neither HBV-related hepatitis nor HCC were observed. No baseline patients' features were found to be significantly associated with the likelihood of HBsAg reappearance after HBIG withdrawal, including the presence of HCC at transplantation.

Conclusions: HBIG could be safely withdrawn in HBV mono-infected LT recipients on long-term combination HBIG plus third generation NAs.

Keywords: HBV‐DNA; entecavir; hepatitis B immunoglobulins; hepatocellular carcinoma; liver transplantation; recurrent hepatitis B; tenofovir alafanamide fumarato; tenofovir disoproxil fumarato.

PubMed Disclaimer

References

    1. P. Burra, G. Germani, R. Adam, et al., “Liver Transplantation for HBV‐Related Cirrhosis in Europe: An ELTR Study on Evolution and Outcomes,” Journal of Hepatology 58 (2013): 287–296.
    1. L. S. Belli, G. Perricone, R. Adam, et al., “Impact of DAAs on Liver Transplantation: Major Effects on the Evolution of Indications and Results. An ELITA Study Based on the ELTR Registry,” Journal of Hepatology 69 (2018): 810–817.
    1. R. Adam, V. Karam, V. Cailliez, et al., “2018Annual Report of the European Liver Transplant Registry (ELTR)–50‐Year Evolution of Liver Transplantation,” Transplant International 31 (2018): 1293–1317, https://doi.org/10.1111/tri.13358.
    1. S. Todo, A. J. Demetris, D. Van Thiel, L. Teperman, J. J. Fung, and T. E. Starzl, “Orthotopic Liver Transplantation for Patients With Hepatitis B Virus‐Related Liver Disease,” Hepatology 13 (1991): 619–626.
    1. D. Samuel, R. Muller, G. Alexander, et al., “Liver Transplantation in European Patients With the Hepatitis B Surface Antigen,” New England Journal of Medicine 329 (1993): 1842–1847.

LinkOut - more resources